EFFECTS OF SHORT-TERM ADMINISTRATION OF DOBUTAMINE ON LEFT-VENTRICULAR PERFORMANCE, EXERCISE CAPACITY, NOREPINEPHRINE LEVELS, AND LYMPHOCYTE ADRENERGIC-RECEPTOR DENSITY IN CONGESTIVE HEART-FAILURE

被引:10
作者
GIBELIN, P
SBIRRAZZUOLI, V
DRICI, M
CAMOUS, JP
LAPALUS, P
MORAND, P
机构
[1] Department of Cardiology, Pasteur Hopital, Nice Cedex, 06031
关键词
adrenergic receptors; beta receptors; dobutamine; heart failure; left ventricular performance; lymphocyte; norepinephrine;
D O I
10.1007/BF01856506
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study was designed to determine the feasibility of identifying those patients with chronic heart failure who will be improved by dobutamine infusion. Twenty-two patients with stable heart failure were treated by infusion of an average dobutamine dose of 12.5 ng/kg/min for 36 hours, then again during a 4-hour session once a week for 1 month. Patients were evaluated by clinical, ergometric, and biochemical parameters (plasma norepinephrine and lymphocyte beta-receptor density) before and after every infusion. Hemodynamics were assessed before and during the first dobutamine infusion. A test with isoproterenol was performed prior to the start of dobutamine therapy. All patients exhibited hemodynamic improvement, which peaked at the 12th hour (55% increase in the cardiac index [p<0.01]; 35% reduction in the filling pressure and systemic arterial resistance). Five patients stopped the study prematurely. Nine patients (group 1) were clinically improved according to their NYHA classification. Eight patients (group 2) remained stable or had progressive disease. The lymphocyte beta-receptor density before dobutamine infusion was significantly higher in group 1 than in group 2 (66±12 vs. 46.7±18 fM/mg; p<0.01). Finally, a good correlation (p<0.05) was observed between the beta-receptor level and the isoproterenol dose required to obtain a heart rate of 130 beats/min. © 1990 Kluwer Academic Publishers.
引用
收藏
页码:1105 / 1111
页数:7
相关论文
共 20 条
[1]  
Leier C.V., Webel J., Bush C.A., The cardiovascular effects of the continuous infusion of dobutamine in patients with severe heart failure, Circulation, 56, pp. 468-472, (1977)
[2]  
Liang C.S., Sherman L.G., Doherty J.U., Et al., Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine, Circulation, 69, pp. 113-119, (1984)
[3]  
Unverferth D.V., Blanford M., Kates R.E., Leier C.V., Tolerance to dobutamine after 72 hours continuous infusion, Am J Med, 69, pp. 113-119, (1980)
[4]  
Unverferth D.V., Magorien R.D., Altschuld R., Et al., The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy, Am Heart J, 106, pp. 29-34, (1983)
[5]  
Leier C.V., Huss P., Lewis R.P., Unverferth D.V., Drug-induced conditioning in congestive heart failure, Circulation, 65, pp. 1382-1387, (1982)
[6]  
Colucci W.S., Wright R.F., Braunwald E., New position inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical development, N Engl J Med, 314, pp. 296-299, (1986)
[7]  
Hoyer D., Engel G., Berthold R., Binding characteristics of (+), (±), a,d (−)-(<sup>125</sup> idocyanopindolol) in guinea pig left ventricle membranes, Naunyn Schmiedeberg's Arch Pharmacol, 31, pp. 319-320, (1982)
[8]  
Maskin C.S., Forman R., Sonnenblick E.H., Et al., Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure, Am J Cardiol, 51, pp. 177-182, (1983)
[9]  
Bristow, Ginsburg R., Minobe W., Et al., Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts, N Engl J Med, 307, pp. 205-211, (1982)
[10]  
Anderson K.E., Adrenergic mechanism in congestive heart failure, Acta Med Scand, 70, pp. 37-44, (1986)